Medicare AdvantageCoverageMedium impact
MA07.027h, Autonomic Nervous System Testing
Independence Blue Cross·Cardiology, Endocrinology, Neurology +2 more·Medical Policy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued MA07.027h on 03/04/2026 to reaffirm the Company's position on autonomic nervous system (ANS) testing. The policy clarifies that ANS testing using noninvasive, portable, automated devices remains experimental/investigational, while formal laboratory-based diagnostic testing is covered only for specific clinical indications. The BILLING REQUIREMENT header has been removed from the policy structure. Billing teams must ensure claims for ANS testing (CPT 95921, 95922, 95923) meet documented medical necessity criteria and are not submitted for screening purposes.
Action Required
By March 4, 2026: Billing team must update claim submission procedures and denial prevention protocols for ANS testing. (1) Verify all claims for CPT 95921, 95922, and 95923 include documentation of one of the covered medical necessity indications (e.g., evaluation of vasomotor instability after exclusion of common causes, assessment of diabetic autonomic neuropathy, syncope differentiation). (2) Implement system-level rules to deny or hold claims submitted for screening purposes or without documented clinical indications. (3) Remove any billing templates or prior authorization requirements tied to the removed BILLING REQUIREMENT section. (4) Train billing staff that noninvasive portable automated ANS testing devices remain experimental and are not covered—only formal laboratory-based testing with covered diagnoses qualifies. (5) Verify all supported ICD-10 diagnosis codes match the policy's medically necessary list. Failure to enforce medical necessity criteria will result in higher claim denial rates from Independence Blue Cross Medicare Advantage plans.